
Humana Individual Plans is the direct-to-consumer insurance product line of Humana Inc. (NYSE: HUM), headquartered in Louisville, Kentucky. It sells standalone dental, vision, hearing, and supplemental health products to individuals who do not have employer or comprehensive medical coverage. The line is distinct from Medicare Advantage and does not include ACA-compliant major medical insurance, which Humana exited in 2018.
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Humana Individual Plans | Humana Inc. | Wholly owned |
Humana has sold individual health products for decades, including comprehensive individual medical coverage until its exit from that market effective January 1, 2018. What remains today is the supplemental and specialty individual portfolio: standalone dental plans (Humana Dental), vision plans (Humana Vision), hearing coverage, and supplemental products such as accident, critical illness, and hospital indemnity insurance.
The line serves two roles: it provides coverage to consumers whose employer or Medicare plans do not include these benefits, and it functions as an entry product that builds brand familiarity ahead of Medicare eligibility. Individual dental is particularly significant, as Medicare does not cover routine dental care, making standalone dental a high-demand product for seniors.
What does Humana own?
Humana owns a portfolio of health insurance and healthcare service brands organized under the Humana master brand and the CenterWell service brand. The portfolio includes Humana Medicare (Medicare Advantage plans), Humana Medicaid (managed care in 13 states), Humana Marketplace (ACA exchange plans), Humana Pharmacy (prescription drug services), CenterWell (senior primary care clinics, pharmacy, and home health), Humana Group Plans (employer-sponsored specialty products), and Humana Individual Plans (individual and family coverage).
Is Humana publicly traded?
Yes. Humana Inc. trades on the New York Stock Exchange under ticker symbol HUM. The company has been publicly traded since its corporate restructuring in the 1990s and is a component of major healthcare sector indices. Its market capitalization fluctuates with earnings performance and Medicare Advantage policy developments.
Who founded Humana?
Humana was founded in 1961 by David A. Jones Sr. and Wendell Cherry in Louisville, Kentucky, originally as a nursing home company called Extendicare Inc. The company pivoted to hospital management in the 1970s and then to health insurance in 1993, when it spun off its hospital operations. Jones served as CEO for decades and remained chairman until his retirement.
Where is Humana headquartered?
Humana is headquartered in Louisville, Kentucky, USA. The company has maintained its headquarters in Louisville since its founding in 1961. Humana operates major offices and care delivery facilities across the United States to support its national Medicare Advantage and Medicaid operations.
How many brands does Humana own?
Humana owns 8 major brands and product lines across its health insurance and healthcare services portfolio. These include Humana Medicare, Humana Medicaid, Humana Marketplace, Humana Pharmacy, Humana Healthcare Services, CenterWell, Humana Group Plans, and Humana Individual Plans. The company uses a focused brand strategy rather than a broad multi-brand portfolio.
Who owns Humana?
Humana is publicly owned with shares trading on the NYSE under ticker HUM. Ownership is distributed among institutional investors, mutual funds, and individual shareholders. No single shareholder holds a controlling interest. Major institutional holders include Vanguard Group, BlackRock, and State Street Corporation. The company operates independently without any parent organization.
What is Humana's revenue?
Humana reported FY2025 revenue of $129.7 billion, up from $117.8 billion in FY2024. For FY2026, the company guided to total revenue of at least $160 billion. The Insurance segment generated $124.6 billion in FY2025 revenue, representing 96.3% of consolidated premiums and services revenue. The company's revenue is heavily concentrated in Medicare Advantage, which accounted for 82.6% of Insurance segment premiums in FY2025.
Is Humana involved in any legal proceedings?
Yes. Humana is appealing a federal court's October 2025 decision rejecting its challenge to CMS Star Ratings methodology. The company also faces an ongoing DOJ investigation into Medicare Advantage risk adjustment practices. Additionally, Humana is subject to routine litigation related to claim denials and coverage decisions, which is typical for large health insurers. The company discloses material legal matters in its SEC filings.
The products address coverage gaps in Medicare and employer plans, particularly dental, vision, and hearing benefits absent from Original Medicare. The direct-to-consumer model extends access to underinsured populations.
Humana's dental and vision products have been recognized in consumer insurance rankings for affordability and coverage breadth. The line carries the parent brand's J.D. Power and A.M. Best standing rather than separate recognition.
Product Confusion: The brand name causes confusion among consumers seeking comprehensive health insurance; Humana's marketplace exit in 2018 means shoppers seeking "individual health insurance" often expect major medical coverage the company does not offer.
Waiting Periods and Coverage Limits: Supplemental dental and vision products carry waiting periods, annual maximums, and network restrictions that generate periodic consumer complaints about coverage expectations.
Marketing Practices: Direct-to-consumer insurance marketing is subject to state insurance department oversight; occasional advertising and telemarketing complaints occur across the supplemental industry.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| State Farm | USA | 1922 | Niche player | United states | All-ages | |
| Humana | USA | 2014 | Discontinued | United states | All-ages |
InsuranceOwned by State Farm Mutual Automobile Insurance Company
State Farm's health insurance product line, covering Medicare Supplement and supplemental health products, which posted a $189 million underwriting loss on $756 million in premiums in 2025.
Healthcare PharmaceuticalsOwned by Humana Inc.
Humana's former individual health insurance marketplace line, which the company exited effective 2018 and no longer offers.
Market Positioning: Humana Individual Plans competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Humana Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Boots is the UK's leading pharmacy-led health and beauty retailer, founded in 1849, now operating as The Boots Group under Sycamore Partners since August 2025.
Boots is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Duane Reade is a New York City drugstore chain owned by Walgreen Co. under Sycamore Partners, operating approximately 90 stores across the five boroughs.
Duane Reade is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by Walgreens Boots Alliance
Walgreens is the largest U.S. pharmacy retail brand, operating roughly 8,000 stores. It went private in August 2025 under Sycamore Partners as a standalone company.
Walgreens is privately owned, unlike Humana Individual Plans which is under a publicly traded parent company.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.